Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

Tumor immunotherapy based on the use of chimeric antigen receptor modified T cells (CAR T cells) is a promising approach for the treatment of refractory hematological malignancies. However, a robust response mediated by CAR T cells is observed only in a minority of patients and the expansion and per...

Descripción completa

Detalles Bibliográficos
Autores principales: Otáhal, Pavel, Průková, Dana, Král, Vlastimil, Fabry, Milan, Vočková, Petra, Latečková, Lucie, Trněný, Marek, Klener, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839314/
https://www.ncbi.nlm.nih.gov/pubmed/27141398
http://dx.doi.org/10.1080/2162402X.2015.1115940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839314/
https://www.ncbi.nlm.nih.gov/pubmed/27141398
http://dx.doi.org/10.1080/2162402X.2015.1115940

Ejemplares similares